北京大学学报(医学版) ›› 2014, Vol. 46 ›› Issue (4): 519-523.

• 论著 • 上一篇    下一篇

伴有膀胱过度活动症症状的良性前列腺增生患者尿液中脑源性神经营养因子的表达

胡浩,许克新△,张晓鹏,方志伟,陈京文,霍飞,王栋,王晓峰   

  1. (北京大学人民医院泌尿外科,北京100044)
  • 出版日期:2014-08-18 发布日期:2014-08-18

Expression of brainderived neurotrophic factor in urine of patients with benign prostatic hyperplasia  complicated overactive bladder symptoms

HU Hao, XU Ke-xin△, ZHANG Xiao-peng, FANG Zhi-wei, CHEN Jing-wen, HUO Fei, WANG Dong, WANG Xiao-feng   

  1. (Department of Urology, Peking University People’s Hospital, Beijing 100044, China)
  • Online:2014-08-18 Published:2014-08-18

摘要: 目的:探讨伴有膀胱过度活动症(overactive bladder,OAB)症状的良性前列腺增生患者尿液中脑源性神经营养因子(brainderived neurotrophic factor,BDNF)的表达水平,以及其与OAB症状严重程度的相关性。方法:根据纳入标准和排除标准共纳入178例拟行经尿道前列腺电切术的良性前列腺增生患者,行常规术前检查及尿动力学检查,采用国际前列腺症状评分表和OAB症状评分表进行症状评估,采用ELISA方法检测患者尿液BDNF表达水平,结果用尿液标本的肌酐(Cr)值进行标准化BDNF/Cr(mg/mol)。结果:中度和重度下尿路症状患者尿液BDNF/Cr平均值分别为(1.189±0.753) mg/mol和(1.817±1.110) mg/mol (P<0.001)。梗阻Ⅲ~Ⅵ级患者尿液BDNF/Cr平均值分别为(1.382±0.945) mg/mol、(1.435±0.938) mg/mol、(1.640±1.104) mg/mol和(1.653±1.019) mg/mol (P>0.05),BDNF/Cr值与梗阻的严重程度无显著的相关关系(r=0.103,P=0.173)。不伴OAB症状和伴OAB症状患者的尿液BDNF/Cr平均值分别为(0.297±0.183) mg/mol和(1.913±0.843) mg/mol (P<0.001)。轻度、中度和重度OAB症状患者的尿液BDNF/Cr平均值分别为(1.501±0.543) mg/mol、(1.806±0.703) mg/mol和(2.560±0.979) mg/mol (P<0.05),尿液BDNF/Cr值与OAB症状的严重程度呈显著的相关关系(r=0.743,P<0.001)。不伴逼尿肌过度活动症状和伴逼尿肌过度活动症状患者的尿液BDNF/Cr平均值分别为(1.194±1.013) mg/mol和(1.917±0.866) mg/mol (P<0.001)。结论:中度和重度下尿路症状的良性前列腺增生患者尿液中BDNF表达水平与梗阻程度没有明显相关性;与不伴有OAB症状的良性前列腺增生患者相比,伴有OAB症状的患者尿液中BDNF的表达水平会明显升高,且与OAB症状的严重程度相关。

关键词: 脑源性神经营养因子, 前列腺增生, 膀胱, 过度活动性

Abstract: Objective:To investigate the expression of urinary brainderived neurotrophic factor (BDNF) in benign prostatic hyperplasia patients with overactive bladder (OAB) symptoms and its correlation with the severity of OAB symptoms. Methods: According to the inclusion and exclusion criteria, a total of 178 patients with benign prostatic hyperplasia who were to undergo transurethral resection of prostate (TURP) were enrolled in this study. All the patients had accepted basic preoperative evaluations, as well as an assessment of their International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS). The patients who had been scheduled for surgery had to take the urodynamic assessment. Urinary BDNF levels were measured by the enzymelinked immunosorbent assay (ELISA) and the results were further normalized to the concentration of urinary creatinine (BDNF/Cr, mg/mol). Results: The urinary BDNF/Cr levels of the patients with moderate and severe lower urinary tract symptoms were (1.189±0.753) mg/mol and (1.817±1.110) mg/mol (P<0.001). The urinary BDNF/Cr levels of the patients with grades Ⅲ-Ⅵ obstruction were (1.382±0.945) mg/mol, (1.435±0.938) mg/mol, (1.640±1.104) mg/mol, and (1.653±1.019) mg/mol, respectively (P>0.05). There was no correlation between the urinary BDNF/Cr levels and the severity of obstruction (r=0.103, P=0.173). The urinary BDNF/Cr levels in the patients with and without OAB symptoms were (1.913±0.843) mg/mol and (0.297±0.183) mg/mol (P<0.001). The urinary BDNF/Cr levels in the patients with mild, moderate and severe OAB symptoms were (1.501±0.543) mg/mol, (1.806±0.703) mg/mol and (2.560±0.979) mg/mol, respectively (P<0.05). There was a correlation between the urinary BDNF/Cr levels and the severity of OAB symptoms (r=0.743, P<0.001). The urinary BDNF/Cr levels in the patients with urodynamic detrusor overativity were significantly higher than those without detrusor overativity [(1.917±0.866) mg/mol and (1.194±1.013) mg/mol, P<0.001]. Conclusion: There is no correlation between urinary BDNF and severity of obstruction in benign prostatic hyperplasia patients with moderate and severe lower urinary tract symptoms. The urinary BDNF levels in patients with OAB symptoms are elevated compared with patients without OAB symptoms, and are correlated with the severity of OAB symptoms.

Key words: Brain-derived neurotrophic factor, Prostatic hyperplasia, Urinary bladder, overactive

[1] 李慎谟, 苏丹丹, 林己煜, 宋昊东, 马潞林, 侯小飞, 王国良, 张洪宪, 叶剑飞, 张树栋. 腹腔镜下膀胱癌根治术同期行肾输尿管全长切除术的预后分析[J]. 北京大学学报(医学版), 2025, 57(5): 961-966.
[2] 缪祺, 洪保安, 张学舟, 孙志鹏, 王维, 王宇轩, 薄予轩, 赵佳晖, 张宁. 膀胱癌合并冠心病患者行经尿道膀胱肿瘤切除术围手术期抗血小板药物管理[J]. 北京大学学报(医学版), 2025, 57(4): 698-703.
[3] 左超, 王国立, 杨昆霖, 车新艳, 孟一森, 张凯. 前列腺体积不同的患者经尿道光纤铥激光前列腺剜除术的有效性及安全性比较[J]. 北京大学学报(医学版), 2025, 57(4): 711-716.
[4] 黄万伟, 沙显燊, 张艺宝, 伍国豪, 骆峰, 陈智慧, 叶东明, 李学松, 赖彩永. 完全3D腹腔镜回肠代双侧输尿管联合膀胱扩大术修复放射治疗后双侧输尿管狭窄并膀胱挛缩[J]. 北京大学学报(医学版), 2025, 57(4): 789-795.
[5] 刘宁, 满立波, 何峰, 黄广林, 翟建坡. 良性前列腺增生患者排尿中断症状与尿动力学指标的相关性[J]. 北京大学学报(医学版), 2025, 57(2): 328-333.
[6] 柯涵炜, 王起, 许克新. 优化环磷酰胺剂量在间质性膀胱炎/膀胱疼痛综合征啮齿动物模型中的应用[J]. 北京大学学报(医学版), 2024, 56(5): 908-912.
[7] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[8] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报(医学版), 2024, 56(4): 589-593.
[9] 李晋娜,许丽娜,李敏,宋怡,张静,贾龙斌. 急性脑梗死患者血清BDNF、IL-18、hs-CRP水平与血管性认知障碍的相关性[J]. 北京大学学报(医学版), 2024, 56(4): 708-714.
[10] 刘欢锐,彭祥,李森林,苟欣. 基于HER-2相关基因构建风险模型用于膀胱癌生存预后评估[J]. 北京大学学报(医学版), 2023, 55(5): 793-801.
[11] 辛鹏,张昊,姜振明. 膀胱内灌注电灼联合水扩张法治疗女性间质性膀胱炎[J]. 北京大学学报(医学版), 2023, 55(5): 865-870.
[12] 许素环,王蓓蓓,庞秋颖,钟丽君,丁炎明,黄燕波,车新艳. 等体温膀胱冲洗对经尿道前列腺电切术患者干预效果的meta分析[J]. 北京大学学报(医学版), 2023, 55(4): 676-683.
[13] 李志华,黄燕波,庞秋颖,于书慧,陈宇珂,李德润. 膀胱阴道瘘修补术后患者生存质量和心理状态调查[J]. 北京大学学报(医学版), 2023, 55(1): 190-193.
[14] 王飞,秦彩朋,杜依青,刘士军,李清,徐涛. 中危非肌层浸润性膀胱癌的最佳膀胱镜监测强度[J]. 北京大学学报(医学版), 2022, 54(4): 669-673.
[15] 朱琳,张维宇,许克新. 环磷酰胺诱导SD大鼠膀胱疼痛综合征模型的有效性[J]. 北京大学学报(医学版), 2022, 54(4): 735-740.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!